GOSSAMER BIO, INC. (GOSS) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2024-12-31..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2024-12-31..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2024-12-31..
Borrowing debt
Overview →Financial period ending 2024-12-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2024-12-31. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2024-12-31. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2024-12-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 0.00 USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 0.00 USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | 294.52M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 315.29M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | (m) | (m) | $0.00 | $0.00 | (m) | $294.52M | $315.29M | (m) |
| 2024-09-30 | (m) | (m) | $0.00 | $0.00 | (m) | $327.03M | $350.88M | (m) |
| 2024-06-30 | (m) | (m) | $0.00 | $0.00 | (m) | $354.49M | $373.45M | (m) |
| 2024-03-31 | (m) | (m) | $9.59M | $0.00 | (m) | $244.39M | $259.36M | (m) |
| 2023-12-31 | (m) | (m) | $11.61M | $814.00K | (m) | $296.43M | $311.92M | (m) |
| 2023-09-30 | (m) | (m) | $11.61M | $3.63M | (m) | $328.89M | $347.93M | (m) |
| 2023-06-30 | (m) | (m) | $11.61M | $6.44M | (m) | $162.13M | $181.75M | (m) |
| 2023-03-31 | (m) | (m) | $11.61M | $9.22M | (m) | $201.86M | $219.91M | (m) |
| 2022-12-31 | (m) | (m) | $11.61M | $11.99M | (m) | $255.68M | $272.45M | (m) |
| 2022-09-30 | (m) | (m) | (m) | $14.83M | (m) | $304.38M | $323.54M | (m) |
| 2022-06-30 | (m) | (m) | (m) | $17.64M | (m) | $222.16M | $245.84M | (m) |
| 2022-03-31 | (m) | (m) | (m) | $29.17M | (m) | $271.62M | $294.68M | (m) |
| 2021-12-31 | (m) | (m) | (m) | $29.08M | (m) | $325.22M | $343.66M | (m) |
| 2021-09-30 | (m) | (m) | (m) | $28.99M | (m) | $366.02M | $387.04M | (m) |
| 2021-06-30 | (m) | (m) | (m) | $28.91M | (m) | $405.92M | $432.51M | (m) |
| 2021-03-31 | (m) | (m) | (m) | $28.82M | (m) | $453.30M | $482.47M | (m) |
| 2020-12-31 | (m) | (m) | (m) | $28.74M | (m) | $512.63M | $539.43M | (m) |
| 2020-09-30 | (m) | (m) | (m) | $28.66M | (m) | $555.38M | $584.18M | (m) |
| 2020-06-30 | (m) | (m) | (m) | $28.64M | (m) | $600.36M | $625.08M | (m) |
| 2020-03-31 | (m) | (m) | (m) | $28.55M | (m) | $346.17M | $371.48M | (m) |
| 2019-12-31 | (m) | (m) | (m) | $28.46M | (m) | $401.83M | $426.60M | (m) |
| 2019-09-30 | (m) | (m) | (m) | $28.37M | (m) | $446.47M | $469.75M | (m) |
| 2019-06-30 | (m) | (m) | (m) | $28.28M | (m) | $464.00M | $507.17M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |